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Purpose: The study was conducted to determine the outcome in the United States after endovascular repair (EVAR) of
infrarenal abdominal aortic aneurysms (AAAs) in patients at high-risk for open surgery by using independently audited,
high-compliance, chart-verified data sets, and to compare those results with open surgery.
Methods:High-risk was defined to match a recent European trial (EVAR2) and included age of >60 years with aneurysm
size of >5.5 cm, plus at least one cardiac, pulmonary, or renal comorbidity. Data from five multicenter investigational
device exemption clinical trials leading to Food and Drug Administration (FDA) approval were analyzed. Of 2216 EVAR
patients, 565 met the high-risk criteria. Of 342 surgical controls (OPEN), 61 met high-risk criteria. Primary outcome
comparisons included AAA-related death, all-cause death, and aneurysm rupture. Secondary measures were endoleak,
AAA sac enlargement, and migration.
Results: Average age of the high-risk EVAR subset was 76 7 years vs 74 6 years OPEN (P 0.07), mean EVAR AAA
size was 6.4  0.8 cm vs 6.6  1.0 cm OPEN (P  .33), and average EVAR follow-up was 2.7 years vs 2.5 years OPEN.
The 30-day operative mortality was 2.9% in EVAR vs 5.1% in OPEN (P  .32). The AAA-related death rate after EVAR
was 3.0% at 1 year and 4.2% at 4 years compared with 5.1% at both time points after OPEN (P  .58). Overall survival
at 4 years after EVAR was 56% vs 66% in OPEN (P  .23). After treatment, EVAR successfully prevented rupture in
99.5% at 1 year and in 97.2% at 4 years.
Conclusions: Endovascular repair of large infrarenal AAAs in anatomically suited high-surgical-risk patients using
FDA-approved devices in the United States is safe and provides lasting protection from AAA-related mortality. EVAR
mortality remained comparable with OPEN up to 4 years. The decision to treat AAAs in patients with advanced age and
significant comorbidities must be individualized and carefully considered, but repair provides excellent protection from
AAA-related death. (J Vasc Surg 2006;44:229-36.)From the Department of Surgery, Division of General Surgery and
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doi:10.1016/j.jvs.2006.04.034The Society for Vascular Surgery (SVS) established a
database for endovascular aneurysm repair (EVAR) in 1998
to evaluate the 4-year outcome of patients with infrarenal
abdominal aortic aneurysms (AAAs).1,2 The database is
populated with results from the five multicenter, controlled
clinical trials used by the United States Food and Drug
Administration (FDA) for clinical use approval of the An-
Cure (Guidant, Indianapolis, Ind) AneuRx (Medtronic,
Minneapolis, Minn), Excluder (W. L. Gore & Assoc., Flag-
staff, Ariz) PowerLink (Endologix, Irvine, Calif), and Ze-
nith (Cook, Bloomington, Ind) endovascular grafts. Each
of these investigational device exemption (IDE) trials com-
pared EVARwith open surgical repair (OPEN); as required
by the FDA, the accuracy of data collection was confirmed
and verified by independent audit. The results of the indi-
vidual trials and the overall SVS database have been previ-
ously published.3-9
A recent European randomized trial, EVAR Trial 2
(EVAR2) examined the safety and efficacy of EVAR in
patients who would be considered high risk or unsuitable
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analysis, since the relative benefit of EVAR compared with
OPEN may be greatest in those patients at high risk for
traditional surgery. Mortality results of EVAR2 (9% at 30
days and 64% at 4 years in the EVAR arm) caused concern
that EVAR may offer no advantage compared with the
natural history of untreated AAAs in high-risk patients. The
purpose of the current analysis was to determine the short-
term and 4-year outcome measures of EVAR in equivalent
high-surgical-risk patients in the United States, using the
most accurate and detailed data available, and to compare
that with OPEN surgery in light of the natural history of
untreated AAAs and the EVAR2 trial.
METHODS
Clinical data from the five US IDE clinical trials sub-
mitted by themanufacturers to the FDA for device approval
are included in the AAA Database. The exact methods of
each of these prospective analyses have been published.3-8
To match EVAR2, high risk was defined as age 60 years,
preprocedure aneurysm diameter5.5 cm, and at least one
of the following comorbidities: symptomatic congestive
heart failure, valvular heart disease, cardiac arrhythmia,
chronic obstructive pulmonary disease (COPD), chronic
renal failure, or serum creatinine value of 2.6 mg/
dL.10,11 The pooled data from five US IDE trials contained
2558 patients. Selection criteria between EVAR andOPEN
in these series were comparable, as reflected by the instruc-
tions for use of the devices. The only substantial difference
among the studies was a greater neck angle exclusion
threshold for the Zenith device. Of these, 565 EVAR
patients and 61 OPEN patients met this high-risk defini-
tion. The remaining 1651 EVAR and 281 OPEN patients
were considered normal risk.
The primary outcome measures of aneurysm repair
were (1) operative mortality, defined as death during the
initial hospitalization or death from any cause 30 days of
the index procedure; (2) aneurysm-related mortality, de-
fined as death from any cause 30 days of the index
procedure, death 30 days of a secondary procedure or
surgical conversion, or any death due to aneurysm rupture
or graft complication; (3) all-cause mortality, and (4) an-
eurysm rupture after repair. Secondary outcome measures
for endovascular grafts were endoleak, aneurysm sac en-
largement, and endograft migration. Aneurysm sac en-
largement was defined as an aneurysm diameter increase of
5 mm compared with predischarge. It is important to
note that onemanufacturer’s protocol defined enlargement
at 5 mm based on 30-day results rather than on predis-
charge imaging. Otherwise, increase in aneurysm size is
defined as 5 mm from predischarge. Migration was de-
fined as longitudinal movement 5 mm relative to ana-
tomic landmarks determined at the time of the initial
endovascular procedure. The 4-year mortality of the high-
risk EVAR patient subset was also compared with the
normal-risk group in the US IDE data set.
Statistical methods. Baseline characteristics of EVAR
and OPEN were compared using the two-tailed t test forcontinuous variables and the 2 or Fisher exact, as neces-
sary, for discrete/categoric data. Descriptive statistics are
listed as mean  standard deviation for continuous vari-
ables and percent (frequency) for categoric variables.
Kaplan-Meier estimates, using the log-rank test, were used
to compare the primary outcome between groups for free-
dom from death (ie, survival), aneurysm-related death, and
rupture. Cox proportional hazards models were used to
estimate hazard ratios and 95% confidence intervals. A
hazard ratio1 indicates a better outcome, on average, for
patients in the EVAR group, whereas a value1 indicates a
worse outcome for patients in that group. Differences were
considered significant if P  .05. Statistical analyses were
performed by New England Research Institutes, Inc
(NERI), in Watertown, Mass. All data were analyzed using
SAS system software (SAS Institute, Cary, NC). All data
figures were generated using S-PLUS (Insightful Corpora-
tion, Seattle, Wash).
RESULTS
Patient population. The numbers of high-risk pa-
tients from each of the IDE clinical trial included in the
AAA Database are summarized in Table I. Baseline demo-
graphic information and comorbid factors are listed in
Table II. The only statistically significant difference be-
tween EVAR and OPEN groups before aneurysm treat-
ment was gender (89% male in EVAR vs 67% OPEN, P 
.01). EVAR patients were approximately 1.5 years older
(75.7 vs 74.2 years, P  .07). OPEN patients were more
likely to have COPD (71% vs 61%, P  .13) (Table III, A).
EVAR and OPEN had comparable prevalence of prior
myocardial infarction (41% EVAR, 38% OPEN), conges-
tive heart failure (26% EVAR, 16%OPEN), coronary artery
disease (70% EVAR, 67% OPEN), and renal insufficiency
(7% EVAR, 8% OPEN). There was a trend towards more
angina in the EVAR group (31% EVAR vs 19%OPEN, P
.14), but it was not statistically significant. There was no
statistically significant difference in preoperative aneurysm
size between EVAR and OPEN, with a mean aneurysm
diameter 6.4 0.8 cm in EVAR patients and 6.6 1.0 cm
in OPEN. Mean postoperative follow-up time for the
EVAR group was 2.7  1.7 years (maximum, 7.1 years)
compared with 2.5  1.7 years (maximum, 6.6 years) for
Table I. Number of patients within each investigational
device exemption trial who met the high-risk definition
EVAR
(n  565)
OPEN
(n  61)
AnCure (Guidant) 111 25
AneuRx (Medtronic) 285 9
Excluder (WL Gore) 55 19
PowerLink (Endologix) 24 8
Zenith (Cook) 90 0
EVAR, Endovascular aneurysm repair; OPEN, open surgical aneurysm
repair.OPEN.
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of the primary end points, operative mortality, AAA-related
mortality, all-cause mortality, and AAA rupture for EVAR
patients extended to 4 years as shown in Fig 1, 2, and 3.
There were no statistically significant differences among the
various devices in primary outcome measures.
Operative mortality. The 30-day operative mortality
for EVAR in this high-risk patient cohort was 2.9% com-
pared with 5.1% for OPEN (hazard ratio, 0.541; 95%
confidence interval, 0.1577 to 1.8572; P  .32). Use of
general anesthesia (n 142) did not affect mortality (2.8%
general anesthesia, 2.7% other forms of anesthesia, log-rank
P  .945).
AAA-related death. One AAA-related death oc-
curred in the interval from 30 days to 1 year in the EVAR
group and none in OPEN. The AAA-related death rate at 1
year was 3.0% for EVAR and 5.1% for OPEN (P  .37 by
Kaplan-Meier log-rank test). Four additional AAA-related
deaths occurred in the EVAR group from years 1 to 4.
Thus, freedom from AAA-related death after EVAR was
97% at 30 days and 96% at 4 years by Kaplan-Meier analysis.
After OPEN repair, freedom from AAA-related death was
95% at 30 days and remained at that level to 4 years (Fig 1)
Table II. Demographics and procedural information by tr
EVAR (n 
Preoperative variables
Age 75.7  7.1 (6
AAA diameter (mm) 64.2  8.4 (5
Gender (male) 89.2 (5
Race (white) 94.9 (5
Myocardial infarction 41.2 (2
Cardiac revascularization 46.7 (2
Angina 31.3 (1
Cardiac valve disease 20 (3
Significant arrhythmia 45.1 (2
Congestive heart failure 25.8 (1
Coronary artery disease 69.5 (1
Hypertension 66.9 (3
Diabetes 13.8 (7
COPD 60.5 (3
Smoking 84.9 (4
Renal insufficiency 6.6 (3
Serum creatinine (mg/dL) 1.3  0.9 (0
Systolic blood pressure (mm Hg) 136.2  23.9 (8
Diastolic blood pressure (mmHg) 76.6  11.3 (5
Ankle-brachial index (left) 1.0  0.2 (0
Ankle-brachial index (right) 1.0  0.2 (0
Postoperative variables
Hospital length of stay (days) 3.5  4.7 (0
Intensive care unit stay (hours) 20.9  49.1 (0
General anesthesia 27.8 (1
Blood product transfusion 21.4 (6
Follow-up time (mean, years) 2.7  1.7 (0
Follow-up time (median, years) 2.2
EVAR, Endovascular aneurysm repair; OPEN, open surgical aneurysm repa
Data are percentages or means  SD (ranges).
*P was calculated using t test for continuous variables and 2 test for categ
†P was calculated using Fisher’s exact test.
‡One patient received an epidural; 3 patients with missing data.(P  .58).All-cause mortality. No significant difference was
found in all-cause mortality between EVAR and OPEN
through the duration of this analysis. Four-year survival was
56% in EVAR and 66% in OPEN (P  .23), as seen in Fig
2. All-cause mortality at 4 years in the high-risk US IDE
EVAR patients was also compared with the normal-risk US
IDE EVAR patients. The high-risk EVAR mortality was
twice that of the non-high-risk patients (44% vs 21%, P 
.0001) (Fig 4).
Rupture. Seven postoperative AAA ruptures occurred
in EVAR patients (1 at 30 days, 6 late) during 1523
patient-years of follow-up; all but one resulted in an AAA-
related death. There was no statistical difference in freedom
from postoperative aneurysm rupture between EVAR pa-
tients (99.5%) and OPEN patients (100%) at 1 year by
Kaplan-Meier analysis (log-rank test, P  .78) (Fig 3).
Freedom from rupture after EVAR was 97% at 4 years. The
difference in rupture between EVAR and OPEN at 4 years
was not significant (P  .58).
Secondary EVAR end points. There were 80
(14.2%) endoleaks reported at 30 days, 99 (17.5%) at 1
year, and 107 (18.9%) at 4 years in the EVAR group, but
the incidence of endoleaks did not significantly vary over
ent arm
% OPEN (n  61) % P*
) 74.2  6.2 (60-87) .07
0) 65.5  9.7 (55-98) .33
65) 67.2 (41/61) .0001
65) 100 (52/52) .09†
65) 37.7 (23/61) .59
75) 44.3 (27/61) .72
54) 19.4 (7/36) .14
0) 21.1 (11/52) .85
65) 32.8 (20/61) .06
65) 16.4 (10/61) .11
90) 67.3 (35/52) .76
65) 72.1 (44/61) .41
5) 16.4 (10/61) .58
65) 70.5 (43/61) .13
65) 77.1 (47/61) .10
5) 8.2 (5/61) .63
9) 1.3  0.4 (0.8-2.3) .79
9) 138.5  21.7 (110-188) .69
0) 80.6  14.0 (52-100) .27
0) 1.0  0.2 (0.6-1.6) .97
0) 1.0  0.2 (0.6-1.6) .86
9.7  8.8 (0-59)  .0001
) 51.2  52.2 (1-330) .0008
10) 90.5 (38/42)‡  .0001†
9) 64.7 (11/17)  .0001†
2.5  1.7 (0-6.6) —
2.7 —
PD, chronic obstructive pulmonary disease.
riables, unless otherwise specified.eatm
565)
0-96
5-11
04/5
34/5
23/5
22/4
42/4
8/19
55/5
46/5
32/1
78/5
8/56
42/5
80/5
7/56
.6-8.
1-22
6-11
.3-2.
.1-2.
-82)
-664
42/5
6/30
-7.1)
ir; CO
oric vatime. The distribution of endoleaks by type was not avail-
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at 30 days, 26 (4.6%) at 1 year, and 62 (11%) at 4 years in
EVAR. No endograft migrations were reported 30 days
of implant in this high-risk EVAR subset. Endograft migra-
tion occurred in four patients (0.7%) at 1 year and in 15
patients (2.7%) at 4 years.
DISCUSSION
The Outcomes Committee of the Society for Vascular
Surgery maintains the AAA Database, which is populated
by data from controlled IDE clinical trials, to monitor the
long-term safety and efficacy of EVAR. Each of the IDE
trials was designed around standardized guidelines to study
a single endograft device for purposes of FDA market
approval. Minor variations among the trials were incorpo-
rated to address device-specific questions. Because there
was no predetermined allocation of EVAR vs OPEN pro-
cedures, the proportion of OPEN patients who met high-
risk criteria varied from 0% to 30% among the US IDE
trials. Nonetheless, these unique, independently audited,
high-compliance, chart-verified data sets related to AAAs
allow accurate identification of patients who would be
considered high-risk for open aneurysm repair.
The nature of FDA studies provides similar long-term
end points and high completeness of follow-up, resulting in
Table III. A, Distribution of comorbidities in the high-ri
EVAR n  565 (
Cardiac 342/565 (60.5
Arrhythmia 255/565 (45.1
Valvular heart disease 38/190 (20.0
Congestive Heart Failure 146/565 (25.8
Pulmonary (COPD) 342/565 (60.5
Renal 37/565 (6.6)
EVAR, Endovascular aneurysm repair; OPEN, open surgical aneurysm repa
Table III. B, Distribution of high-risk cohort by the num
EV
1 high-risk comorbidity
2 high-risk comorbidities
All 3 high-risk comorbidities
EVAR, Endovascular aneurysm repair; OPEN, open surgical aneurysm repa
Table III. C, Comparison of comorbidities in high-risk co
EVAR (US IDE
Cardiac 342/565
Pulmonary (COPD) 342/565
Mean FEV1 Not ava
Renal 37/565
Median creatinine 1.1 mg
EVAR, Endovascular aneurysm repair; IDE, investigational device exemptio
in 1 second.high credibility of the EVAR and OPEN data in the USIDE trials. The results of individual IDE trials have been
published and demonstrate safety and efficacy of EVAR
across the full spectrum of inclusion criteria.3-8 Application
of the EVAR2 high-risk criteria to the US IDE trial data set
identified 565 patients who were certainly more ill, overall,
than the 1651 normal-risk participants (4-year mortality:
44% high risk, 21% normal risk; P  .0001) (Fig 4).
However, despite fitting the EVAR2 definition of high risk,
the US IDE mortality compares favorably with EVAR2 in
short-term (30-day mortality: 2.9% US IDE, 9% EVAR2)
and 4-year (44% US IDE, 64% EVAR2) results. We believe
the US IDE results indicate that EVAR is safe and effective
in most patients with advanced age, large aneurysms, and
high-risk medical comorbidities.10
Previous single-center reports have shown EVAR to be
a safe alternative to OPEN in high-risk patients and octo-
genarians.12-14 Anderson et al15 analyzed the New York
Statewide Planning and Research Cooperative System
(SPARCS) for EVAR and OPEN for the elective treatment
of AAA from 2000 to 2002.15 Over the 3-year study
period, the authors identified an increase in incidence of
hypertension, coronary artery disease, and hyperlipidemia
in patients undergoing EVAR compared withOPEN; how-
ever, despite this increase in comorbidities over time, the
perioperative mortality, postoperative complications, and
hort
OPEN n  61 (%) P
29/61 (47.5) .0498
20/61 (32.8) .0649
11/52 (21.2) .8544
10/61 (16.4) .1051
43/61 (70.5) .1288
5/61 (8.2) .6250
f comorbidity categories (P  .46)
 565 (%) EVAR n  565 (%)
(73.1%) 46 (75.4%)
(26.2%) 14 (23.0%)
(0.7%) 1 (1.6%)
t with EVAR2
565 (%) EVAR210 n  166 (%)
5) 108/166 (65)
5) Not available
1.6 L
) Not available
108mol/L (1.2 mg/dL)
PD, chronic obstructive pulmonary disease; FEV1, forced expiratory volumesk co
%)
)
)
)
)
)ber o
AR n
413
148
4hor
) n 
(60.
(60.
ilable
(6.6
/dLlength of stay were significantly lower for EVAR compared
eurysm rupture (P  .5842).
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 # of events 16 1 3 0 1 
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 Standard error 0.00701 0.00724 0.00849 0.00849 0.00959 
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 # censored 3 9 8 11 16 
 K-M estimate 0.9494 0.9494 0.9494 0.9494 0.9494 
 Standard error 0.0285 0.0285 0.0285 0.0285 0.0285 
Fig 1. Kaplan-Meier curve of freedom from aneurysm-related
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 # at risk  
 # of events 3   5   0 6 1 
 # censored 3 4 8 5 15 
 K-M estimate 0.9494 0.8604 0.8604 0.7092 0.6585 
 Standard error 0.0285 0.0459 0.0459 0.0677 0.0796 
565 545 462 347 233
61 55 46 38 27Fig 2. Kaplan-Meier curve of survival (P  .2312).Freedom from Rupture
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0-30 d 30 d-1 yr 1 d-2 yr 2 yr-3 yr 3 yr-4 yr 
EVAR
 # at risk 399 385 322 228 142 
 # of events 1 1 4 0 1 
 # censored 13 62 90 86 40 
 K-M estimate 0.9975 0.9946 0.9799 0.9799 0.9722 
 Standard error 0.00253 0.00385 0.00825 0.00825 0.0112 
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 # at risk 17 15 12 11 7 
 # of events 0 0 0 0 0 
 # censored 2 3 1 4 2 
 K-M estimate 1.00 1.00 1.00 1.00 1.00 
 Standard error 0.00 0.00 0.00 0.00 0.00 
Fig 3. Kaplan-Meier curve of postoperative abdominal aortic an-Freedom from All-Cause Mortality (High-Risk vs. Non High-Risk)
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 # at risk 565 545 462 347 233 
 # of events 16 59 64 35 30 
 # censored 4 24 51 79 45 
 K-M estimate 0.9715 0.8651 0.7397 0.6516 0.5560 
 Standard error 0.00701 0.0145 0.0191 0.0219 0.0247 
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 Standard error 0.00263 0.00567 0.00791 0.00928 0.0112 
Fig 4. Kaplan-Meier curve of survival (high-risk EVAR vs. non
high-risk EVAR) (P  .0001).
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30-day mortality of EVAR did not reach statistical signifi-
cance compared with the 5.1% mortality of OPEN, but our
analysis was likely underpowered in the OPEN arm based
on the criteria for high risk. The New York State experience
was evaluated for 4770 patients,15 whereas ours had the
data of only 565 patients analyzed.
Various studies evaluating the natural history outcomes
of patients who did not undergo surgery because they were
deemed unsuitable for traditional open repair because of
comorbid factors have confirmed a high incidence of AAA-
related death.16,17 In a prospective, multicenter observa-
tional study of rupture rates in patients unfit for surgery,
Lederle et al16 reported a 1-year rupture rate of 9.4% in
patients with AAAs 5.5 to 5.9 cm in diameter, 19.1% for
patients with AAAs 6.5 to 6.9 cm, and 32.5% for AAAs
7.0 cm. These remarkably high rates of death from AAA
rupture were based on a 46% autopsy rate; thus, the true
incidence of AAA-related death is almost certainly higher.
With an average diameter of 6.4 cm, the US IDE trial
high-risk EVAR group had a 1-year AAA-related mortality
of 3.0%, dramatically less than natural history as reported by
Lederle et al.
Conway et al17 reported on 106 patients deemed unfit
for open aneurysm repair due to comorbid factors. They
identified AAA rupture as the cause of death at 3 years in
36% of AAAs 5.5 to 5.9 cm in diameter, 50% for AAAs 6.0
to 7.0 cm, and 55% for AAAs 7.0 cm. Jones et al18
followed 50 high-risk patients who were turned down for
open AAA repair. Death from AAA rupture at 3 years was
reported in 28% for AAAs 5.0 to 5.9 cm and 41% for AAAs
6.0 cm. At 4 years, the current analysis of the US IDE
EVAR cohort demonstrated AAA-related mortality of 4.3%
in EVAR and 5.1% in OPEN compared with 40% to 50% in
the two natural history studies.17,18
Given the results of these natural history studies, watch-
ful waiting would seem an appropriate clinical recommen-
dation only for those with the most extreme medical co-
morbidities, whereas the minimally invasive EVAR
treatment, intuitively, should offer a relatively greater de-
gree of benefit in those at high risk for open surgery. Results
of EVAR2, however, raise questions about the appropriate-
ness of EVAR over observation in high-risk patients with
large AAAs.10
The EVAR2 trial is a study of 338 patients aged 60
years who had AAAs of at least 5.5 cm in diameter and who
met high-surgical-risk criteria for open repair due to car-
diac, pulmonary, or renal comorbidities. Patients in that
trial were randomized to EVAR or no intervention. The
30-day mortality for EVAR in the EVAR2 trial was 9%.
AAA-related mortality at 4 years was 14% for EVAR and
19% for no intervention (P  NS). Overall, 4-year survival
was only 34% in EVAR and 38% in the no-intervention
group. The authors concluded that EVAR “is not a safe
procedure in such high-risk patients.” Despite comparable
age (76.8 years in EVAR2, 75.7 in US IDE), aneurysm size
(6.4 cm EVAR2, 6.4 cm US IDE), high-risk entry thresh-
olds (cardiac, pulmonary, and renal comorbidities), andincidence of these comorbidities in the two reports, the
30-day mortality for US IDE EVAR was less than one third
that of the EVAR2 trial (2.7% vs 9%). Likewise, at 4 years,
AAA-related mortality was markedly lower in US IDE
EVAR patients at 4% compared with 14% in EVAR2.
Indeed, the overall 4-year survival of 565 high-risk US IDE
EVAR patients was markedly higher than the 166 patients
in EVAR2 (56% US IDE EVAR vs 34% EVAR2). Given
that the 95% confidence interval for EVAR in the US IDE
Database is (0.5066, 0.6054) and that the EVAR2 mortal-
ity does not fall within this interval, the survival rate in US
IDE EVAR is statistically significant, at a .05 level, com-
pared with EVAR2.
There are at least two identifiable explanations of the
large outcomes differences between the high-risk patients
in US IDE EVAR trials and those in EVAR2. First, 14
patients in EVAR2 died preoperatively during the 57-day
interval between randomization and repair. Thus, 52% of
the perioperative deaths (14/27) and 19% of total deaths in
the EVAR arm occurred preoperatively. Nine patients died
from AAA rupture before their elective EVAR date, ac-
counting for 45% of the 20 aneurysm-related deaths in the
EVAR arm of EVAR2. Many of these deaths might not
have occurred with a shorter interval before repair.
Second, the final decision to include a patient in
EVAR2 was delegated to the individual providers at each
hospital (surgeon, radiologist, anesthesiologist, and cardi-
ologist) under a “pragmatism” guideline. Thus, not only
was it necessary for a patient to meet one of the cardiac,
pulmonary, or renal criteria, but the patients also had to fail
the “pragmatism” test to be assigned to EVAR2. In our
retrospective analysis of US IDE EVAR patients, a pragma-
tism analysis could not be applied, but the distribution of
comorbidities is illustrated in Table III, B. Thus, although
the EVAR2 and US IDE high-risk patients were equivalent
in terms of age and AAA size, and the prevalence of cardiac,
renal, and pulmonary risks was comparable (Table III, C),
it is possible that EVAR2 patients were sicker, overall, than
those analyzed in the current report. However, based upon
published results of comorbidities, the US IDE criteria are
more objective than EVAR2, as compared in Table III, C.
The impact of the pragmatism test was not emphasized in
the EVAR2 report, but this additional criterion is likely
another major reason why 30-day mortality in EVAR2 was
9%. This was apparently an extremely ill group of patients,
and it is clear from EVAR2 that there are patients who are
far too ill for any form of AAA therapy. Objective analysis of
comorbidities that would identify these patients should be
further investigated.
All-cause mortality is an important consideration in the
high surgical risk population. As noted, mortality at 4 years
was 44% in this current high-risk EVAR analysis, 21% in the
normal-risk US IDE EVAR patients, and 66% in EVAR2.
Endovascular AAA repair brought about no net beneficial
impact on all-cause mortality in EVAR2, and it was one of
the few trials to be conducted using no intervention as the
control group.Much has beenmade of the lack of mortality
reduction in this trial, but review of the details provides a
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 2 Sicard et al 235possible explanation. In EVAR2, 27% of the deaths (20/
74) in the EVAR arm were aneurysm-related, but six of the
deaths occurred preoperatively, falsely inflating the AAA
death rate in the treatment arm. In the no-treatment arm,
32% of the deaths (22/68) were aneurysm-related, but this
may actually have been falsely low. Forty-seven patients in
the no-treatment arm (22%) crossed over to surgery with
very low mortality, thereby reducing the aneurysm-related
death in the control arm. This clearly biased the results
against EVAR in the intent-to-treat analysis. It would ap-
pear that the most convincing conclusion from EVAR2 is
that large aortic aneurysms constitute a lethal disorder.
Their conclusion regarding lack of all-cause mortality ben-
efit between repair and no treatment should be questioned.
Compared with EVAR2, the US IDE EVAR trials in
similarly high-risk patients provided protection against an-
eurysm-related death with low perioperative mortality.
Roughly 30% of overall mortality in EVAR2 was AAA-
related, whereas AAA-related deaths accounted for only 4%
in US IDE patients. This large incremental difference in
mortality does much to explain why EVAR2 4-year mortal-
ity was 66%, whereas the US trial 4-year overall mortality
was 44%.
Our study has two levels of limitation. First is the low
number of patients in the OPEN arm in the comparison
of EVAR with OPEN in the US IDE data. With only 61
patients in the OPEN arm, our study was underpowered
to identify a difference in mortality. The second level of
limitation relates to comparing the results of our study
with those of EVAR2. The control groups differ; we
compared with OPEN surgery while EVAR2 compared
with no treatment. Furthermore, it is difficult to com-
pare the overall morbidity of our high-risk patients with
those in EVAR2. Only a detailed evaluation of the
cumulative comorbidities and the causes of death could
resolve this question. Finally, the current analysis did not
assess cost-effectiveness or quality-of-life issues that were
addressed in EVAR2.
CONCLUSION
Analysis of EVAR outcomes in high-risk patients en-
rolled in US IDE trials indicates that this treatment is safe
and effective, with results far superior to a recently pub-
lished EVAR2 trial. Analysis to 4 years indicates that EVAR
provides excellent protection from aneurysm rupture and
AAA-related death, with no significant difference from
open surgical controls. A thorough individualized risk/
benefit analysis must be undertaken for each patient who
fits the definition of high risk for surgery, but providers
must remain aware of natural history studies indicating that
AAA rupture and death is the likely fate when watchful
waiting is chosen for patients with large AAAs. High-risk
patients found to have an extremely short life expectancy
from nonaneurysmal disorders may be appropriate candi-
dates for watchful waiting. For the rest, in the presence of
suitable aortic anatomy, EVAR may be the best treatment
option.We acknowledge Kaijun Wang, PhD, MS, from New
England Research Institutes, Inc, for contributing to the
statistical analysis for this manuscript.
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1988;85:1382-84.Submitted Mar 29, 2006; accepted, Apr 19, 2006.INVITED COMMENTARYJaap Buth, MD, PhD, Eindhoven, The Netherlands
The objectives of this article from Sicard et al are two-fold.
First, it is meant to assess the benefit of elective endovascular
aneurysm repair (EVAR) in patients at high-risk for open surgery
and second, compare the obtained outcomes with those of the
EVAR 2 trial published in The Lancet in 2005.1 The conclusions of
the current article were substantially different from those of the
EVAR 2 report. The authors have made a commendable effort to
explain the differences, and understandably, they try to convince
the reader that their conclusion is the correct one.
What is the nature of the substantial differences in the main
outcome events after EVAR in these two studies? The design of the
current analysis is not straightforward. The baseline patient cohort
came from five commercially sponsored nonrandomized investiga-
tional device exemption (IDE) studies, with inherently several
unknown factors. The selection criteria to include a patient, al-
though not specified, most likely varied between the different
studies. Study protocols from device manufacturers have a natural
tendency to avoid the selection of patients with an increased risk of
postoperative complications, including death. Nevertheless, the
authors were able to identify a group of patients at high operative
risk.
The factors determining high-risk patients were probably not
equally balanced between the different studies, and most impor-
tant, no formal meta-analysis methodology was used. Crude min-
imal criteria, requiring the presence of (only) one comorbidity,
sufficed to define a patient as high risk, which contrasted from the
severity of the requirements for patient enrolment in EVAR 2.2
The reader must be puzzled by finding out that a portion of these
patients received open repair despite being considered unfit for
open surgery. The details of why a patient was allocated to EVAR
or open repair were not specified.
From a design point of view, the EVAR 2 trial is far superior.
Supported by an independent governmental grant and with proper
randomization of a large patient group between treatments, EVAR
2 is supposed to provide level I scientific evidence. The details were
less transparent, however, and the fact that to date no straightfor-
ward generally accepted criteria exist to define the patient unfit forIn addition, some disturbing logistic problems occurred dur-
ing the trial. Notably, the significant delay between randomization
and treatment was at the expense of several ruptured aneurysms
before the intervention. All weaknesses were detailed in the discus-
sion of the present article. One of the other flaws in EVAR 2 was
that a number of patients initially were misclassified, as these
patients (crossing-over from watchful waiting to intervention) did
tolerate a secondary AAA procedure well, including open repair in
12 patients.
Where does this leave us? After careful studying the present
article in this journal and the report in The Lancet, it occurs that
there is more than one category of high-risk patients. Considering
the substantial difference in all-cause mortality after 4 years of
follow-up, the average patient in the IDE studies was not nearly as
unfit as most of the patients in EVAR 2. One should note that in
unfit patients, not only the all-cause mortality but also the aneu-
rysm-relatedmortality (including the one-month rate) proportion-
ally increases.3 Perhaps the severest problem of EVAR 2 was that
many patients were too sick for even an endovascular procedure.
What can we learn from these two articles? For intermediately
increased-risk patients, who represent large proportion in the
average vascular surgical practice, the conclusions of the IDE
derived data that EVARmay be the best treatment can be accepted.
In patients with a very short life expectancy, for instance 1 year,3
a policy of nonintervention, as suggested by the EVAR 2 reporters,
definitely is the wiser option.
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